Associate
Claris VenturesCheck size: Claris Ventures does not publish a standard check-size range on its current official site.
Giuditta Magnifico invests or supports investment decisions through Claris Ventures's published strategy: Build and invest in biopharma companies arising from the Italian research ecosystem around transformational therapies for major unmet patient needs.
Exceptional science, strong translational potential, credible intellectual property and teams capable of developing transformational medicines.
Projects outside therapeutics and biopharma, or without strong scientific evidence and Italian ecosystem relevance, are less aligned.
Show the unmet need, mechanism and evidence, IP position, development plan, founding scientific team and milestones to the next value inflection.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Giuditta Magnifico is a current Associate at Claris Ventures, according to the firm's official roster. No education, prior employment or personal deal claims are inferred where the firm does not publish them.